Cost-effectiveness study of the treatment of depression in Mexico;Estudio de costo-efectividad del tratamiento de la depresión en México

Salud Mental

Volumn 33, Issue 4, 2010, Pages 301-308

  del Carmen Lara Muñoz, María ^a,b   Robles García, Rebeca ^b   Orozco, Ricardo ^b   Real, Tania ^b   Chisholm, Dan ^c   Medina Mora, Ma Elena ^b  

^a B Universidad Autonoma de Puebla   (Mexico)

^b INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^c Organización Mundial de la Salud   (Mexico)

Author keywords

Cost effectiveness; Depression; Treatment

Indexed keywords

EID: 79955560302     PISSN: 01853325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, et al. WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004;291:2581-2590.
2. Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-392.
3. Lara MC, Medina-Mora ME, Borges G. Social cost of mental disorders: Disability and work days lost. Results from the Mexican survey of psychiatric epidemiology. Salud Mental 2007;30:4-11.
4. Medina-Mora ME, Borges G, Lara C, Benjet C, et al. Prevalence, service use, and demographic correlates of 12-month DSM-IV psychiatric disorders in México: results from the Mexican National Comorbidity Survey. Psychol Med 2005;35:1-11.
5. Medina-Mora ME, Borges G, Lara MC, Benjet C, et al. Prevalencia de trastornos mentales y uso de servicios: Resultados de la Encuesta Nacional de Epidemiología. Psiquiátrica en México. Salud Mental 2003;26:1-16.
6. Cipriani A, Malvini L, Furukawa TA, Barbui C. Relationship between quality of reports of antidepressant randomized controlled trials and treatment estimates: systematic review, meta-analysis, and meta-regression analysis. J Clin Psychopharmacol 2007;27:352-356.
7. Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry 2009; 70:1219-1229.
8. Borges G, Wang PS, Medina-Mora ME. Lara C, et al. Delay of first treatment of mental and substance use disorders in Mexico. Am J Public Health 2007;97:1638-1643.
9. Lloyd K, Jenkins R. The economics of depression in primary care. Department of Health Initiatives. Br J Psychiatry 1995;27:60-62.
10. Simon GE, Chisholm D, Treglia M, Bushnell D, et al. Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry 2002;24:328-335.
11. Hu TW, He Y, Zhang M, Chen N. Economic costs of depression in China. Soc Psychiatry Psychiatr Epidemiol 2007;42:110-116.
12. Chisholm D. Dollars, DALYs and decisions: economic aspects of the mental health system. Geneva: World Health Organization; 2006.
13. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-1902.
14. Simon GE, Katon WJ, VonKorff M, Unützer J, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry 2001;158(10):1638-1644.
15. Araya R, Flynn T, Rojas G, Fritsch R, et al. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. Am J Psychiatry 2006;163(8):1379-1387.
16. Stant AD, Ten Vergert EM, den Boer PC, Wiersma D. Cost-effectiveness of cognitive self-therapy in patients with depression and anxiety disorders. Acta Psychiatr Scand 2008;117:57-66.
17. De Graaf LE, Gerhards SA, Evers SM, Arntz A, et al. Clinical and costeffectiveness of computerized cognitive behavioral therapy for depression in primary care: design of a randomized trial. BMC Public Health 2008;30:224-228.
18. Knapp M, Romeo R, Mogg A, Eranti S, et al. Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomized controlled trial. J Affect Disord 2008;109:273-285.
19. Murray CJL, Lopez AD. The Global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press; 1996.
20. Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the burden of depression: a population-level analysis of intervention costeffectiveness in 14 epidemiologically-defined sub-regions (WHOCHOICE). Br J Psychiatry 2004;184:393-403.
21. Katon W, Von Korff M, Lin E, Simon G, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999;56:1109-1115.
22. Solomon DA, Keller MB, Leon AC, Mueller TI, et al. Recovery from depression: a 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry 1997;54:1001-1006.
23. Thase ME, Greenhouse JB, Frank E, Reynolds CH, III, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54:1009-1015.
24. Malt UF, Robak OH, Madsbu HP, Bakke O, et al. The Norwegian naturalistic treatment study of depression in primary practice (NORDEP)-I: randomised double blind study. BMJ 1999;318:1180-1184.
25. Chilvers C, Dewey M, Fielding K, Gretton V, et al. Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. BMJ 2001;322:1-5.
26. Araya R, Rojas G, Fritsch R, Gaete J, et al. Treating depression in primary care in low-income women in Santiago,Chile: a randomised controlled trial. Lancet 2003;361:995-1000.
27. World Health Organization. The World Health Report 2001. Mental Health: New Understanding, New Hope. Geneva: World Health Organization; 2001.
28. Callin AE. How much does an inadequate syphillis control program cost a country? Salud Publica Mex 1968;10:611-614.
29. Carlos F, Clark P, Maciel H, Tamayo JA. Direct costs of osteoporosis and hip fracture: an analysis for the Mexican Social Insurance Health Care System. Salud Publica Mex 2009;51:108-113.
30. Ruiz C, Ponce S. Socioeconomic profile and cost of treatment for patients with the acquired immunodeficiency syndrome treated at the Instituto Nacional de la Nutricion «Salvador Zubiran». Revista de Investigacion Clinica 1987;39 (Suppl):139-141.
31. Tellez J. Direct cost of partial epilepsy in Mexico. What is the next step? Arch Med Research 2006;37:808-809.
32. Reynales LM, Campuzano JC, Sesmaez S, Juarez SA, et al. Costs of medical care for acute myocardial infarction attributable to tobacco consumption. Arch Med Research 2006;37(7):871-879.
33. Granados V, Velázquez R, Garduno J, Torres J, et al. Resource utilization and costs of treating severe rotavirus diarrhea in young Mexican children from the health care provider perspective. Revista Investigación Clínica 2009;61:18-25.
34. García F, Del Angel G, Ramírez A, Malvaez M. Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia. Revista Investigación Clínica 2000;52:418-426.
35. García F, Nevarez A, Constantino P, Abud F, et al. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1. Arch Med Research 20069;37:663-673.
36. Munoz M, Nevarez A, Garcia F, Mendieta S, et al. Cost-effectiveness of the treatment of acute and chronic rhinosinusitis at the IMSS. Revista Investigacion Clinica 2007;59:197-205.
37. Martínez P, Medina-Mora ME, Campillo C. Evaluación del costo de utilización de los servicios en la práctica médica general. Salud Mental 1984;7:63-67.
38. Rascón R, Arredondo A, Tirado L, López M. Una aproximación al costo del tratamiento de las enfermedades mentales en México: depresión y esquizofrenia. Salud Mental 1988;21:43-47.
39. Parada I, Arredondo A, Arjonilla S. Costos de hospitalización por farmacodependencia para la población no asegurada en México. Salud Mental 2003;26:17-24.
40. De Gortari E, Castro E, Fernández J. Costs of operating psychiatric hospitals of the Ministry of Health in the Federal District. Salud Publica Mex 1993;35:563-568.
41. Palmer C, Brunner E, Ruiz-Flores L, Paez F, et al. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia. Arch Med Research 2002;33:572-580.
42. López SR, Lara C, Kopelowicz A, Solano S, et al. La Clave to increase psychosis literacy of Spanish-speaking community residents and family caregivers. J Consult Clin Psychol 2009;77:763-774.
43. Páez F, Robles R, Chávez J. Eficacia de una intervención psicológica impartida por un pasante de medicina para disminuir la sintomatología depresiva y ansiosa en mujeres rurales del estado de Jalisco. Trabajo de Investigación presentado en el Encuentro Nacional de Investigadores. Veracruz, México: Secretaría de Salud; 2002.